# Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients

> **NCT00526448** · PHASE4 · UNKNOWN · sponsor: **Hospital Carlos III, Madrid** · enrollment: 384 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** ribavirin
- **DRUG:** ribavirin
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** epoetin beta

## Key facts

- **NCT ID:** NCT00526448
- **Lead sponsor:** Hospital Carlos III, Madrid
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** —
- **Final completion:** 2010-02
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2009-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526448, "Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00526448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*